GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

IMDX · Sep 30, 2025

Insight Molecular Diagnostics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-25-274266General Corporate
Capex intensity88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

403.85% · OPTIONAL · VALID

Operating cash generation45thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-1731.54% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

126.09% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

181.15% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross margin64thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.gross_margin

53.46% · CORE · VALID

Operating margin27thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.operating_margin

-4249.23% · CORE · VALID

R&D intensity82thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1491.54% · OPTIONAL · VALID

SBC intensity55thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

200.38% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/5 normalizedLevel 3Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/5 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20245/8 normalizedLevel 3Mar 31, 20255/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
67.37%
Current
403.85%
Delta
336.47%
Cash Generation Decreased
Previous
-1212.16%
Current
-1731.54%
Delta
-519.38%
Growth Decreased
Previous
398.08%
Current
126.09%
Delta
-271.99%
Inventory Pressure Increased
Previous
133.78%
Current
181.15%
Delta
47.37%
Margin Decreased
Previous
67.57%
Current
53.46%
Delta
-14.11%
Profitability Decreased
Previous
-1900.00%
Current
-4249.23%
Delta
-2349.23%
R And D Intensity Increased
Previous
633.40%
Current
1491.54%
Delta
858.14%
Sbc Intensity Increased
Previous
97.30%
Current
200.38%
Delta
103.09%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · IMDX Fundamental State →Transitioned To · IMDX PROFITABILITY_DECREASED →Transitioned To · IMDX R_AND_D_INTENSITY_INCREASED →Transitioned To · IMDX SBC_INTENSITY_INCREASED →Transitioned To · IMDX Fundamental State →Transitioned To · IMDX CAPEX_INTENSITY_INCREASED →Transitioned To · IMDX CASH_GENERATION_DECREASED →Transitioned To · IMDX GROWTH_DECREASED →Transitioned To · IMDX INVENTORY_PRESSURE_INCREASED →Transitioned To · IMDX MARGIN_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.